Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.

Urbano M, Okwara L, Manser P, Hartmann K, Herndon A, Deutsch SI.

Clin Neuropharmacol. 2014 May-Jun;37(3):69-72. doi: 10.1097/WNF.0000000000000033.

2.

A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders.

Urbano M, Okwara L, Manser P, Hartmann K, Deutsch SI.

J Neuropsychiatry Clin Neurosci. 2015;27(2):133-8. doi: 10.1176/appi.neuropsych.13070155.

PMID:
25923852
3.

D-cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice.

Deutsch SI, Pepe GJ, Burket JA, Winebarger EE, Herndon AL, Benson AD.

Brain Res. 2012 Feb 23;1439:96-107. doi: 10.1016/j.brainres.2011.12.040. Epub 2011 Dec 29.

PMID:
22261249
4.

D-Cycloserine improves sociability in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders with altered Ras/Raf/ERK1/2 signaling.

Burket JA, Benson AD, Tang AH, Deutsch SI.

Brain Res Bull. 2013 Jul;96:62-70. doi: 10.1016/j.brainresbull.2013.05.003. Epub 2013 May 15.

PMID:
23685206
5.

Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.

Farrell LJ, Waters AM, Boschen MJ, Hattingh L, McConnell H, Milliner EL, Collings N, Zimmer-Gembeck M, Shelton D, Ollendick TH, Testa C, Storch EA.

Depress Anxiety. 2013 Aug;30(8):723-31. doi: 10.1002/da.22132. Epub 2013 May 30.

PMID:
23722990
6.

Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress.

Scheeringa MS, Weems CF.

J Child Adolesc Psychopharmacol. 2014 Mar;24(2):69-77. doi: 10.1089/cap.2013.0106. Epub 2014 Feb 7.

7.

Augmenting transcranial direct current stimulation with (D)-cycloserine for depression: a pilot study.

Chan HN, Alonzo A, Martin DM, Mitchell PB, Sachdev P, Loo CK.

J ECT. 2013 Sep;29(3):196-200. doi: 10.1097/YCT.0b013e3182801b09.

PMID:
23792778
8.

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.

Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M.

Arch Gen Psychiatry. 2004 Nov;61(11):1136-44.

PMID:
15520361
9.

A pilot study of D-cycloserine in subjects with autistic disorder.

Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ.

Am J Psychiatry. 2004 Nov;161(11):2115-7.

PMID:
15514414
10.

Effects of D-cycloserine on negative symptoms in schizophrenia.

Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP.

Schizophr Res. 2004 Dec 1;71(2-3):239-48. Review.

PMID:
15474895
11.

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.

Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL.

Am J Psychiatry. 2008 Mar;165(3):335-41; quiz 409. doi: 10.1176/appi.ajp.2007.07050776. Epub 2008 Feb 1.

PMID:
18245177
12.

Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.

Wake R, Miyaoka T, Inagaki T, Furuya M, Ieda M, Liaury K, Kishi K, Horiguchi J.

J Child Adolesc Psychopharmacol. 2013 Jun;23(5):329-36. doi: 10.1089/cap.2012.0108.

PMID:
23782127
13.

An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders.

Taliou A, Zintzaras E, Lykouras L, Francis K.

Clin Ther. 2013 May;35(5):592-602. doi: 10.1016/j.clinthera.2013.04.006.

PMID:
23688534
14.

D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.

Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK.

Int Clin Psychopharmacol. 2007 Jul;22(4):230-7. Erratum in: Int Clin Psychopharmacol. 2007 Sep;22(5):312.

PMID:
17519647
15.

Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.

Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH.

Biol Psychiatry. 2010 Feb 15;67(4):365-70. doi: 10.1016/j.biopsych.2009.07.036. Epub 2009 Oct 6.

PMID:
19811776
16.

D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.

Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC.

Schizophr Res. 2011 Sep;131(1-3):69-74. doi: 10.1016/j.schres.2011.05.029. Epub 2011 Jun 30.

17.

Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disorders.

Burket JA, Herndon AL, Winebarger EE, Jacome LF, Deutsch SI.

Brain Res Bull. 2011 Oct 10;86(3-4):152-8. doi: 10.1016/j.brainresbull.2011.08.001. Epub 2011 Aug 5.

PMID:
21840381
18.

A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders.

Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C.

Am J Psychiatry. 2012 Mar;169(3):292-9. doi: 10.1176/appi.ajp.2011.10050764. Erratum in: Am J Psychiatry. 2012 May;169(5):540.

PMID:
22193531
19.

A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder.

de Kleine RA, Hendriks GJ, Kusters WJ, Broekman TG, van Minnen A.

Biol Psychiatry. 2012 Jun 1;71(11):962-8. doi: 10.1016/j.biopsych.2012.02.033. Epub 2012 Apr 4.

PMID:
22480663
20.

Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders.

Burket JA, Benson AD, Tang AH, Deutsch SI.

Brain Res Bull. 2014 Jan;100:70-5. doi: 10.1016/j.brainresbull.2013.11.005. Epub 2013 Dec 1.

PMID:
24295733
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk